Life Sciences

Researchers developed a screening method that tests thousands of DNA nanostructures simultaneously to find designs cells naturally absorb—a major shortcut for drug developers. The technique uses evolution as a discovery tool, automatically identifying which structures penetrate different cell types, potentially accelerating the pipeline for DNA-based therapeutics from years to months.EN

Researchers found that standard lab techniques for analyzing nanoparticle safety and effectiveness are producing false results by accidentally capturing natural cell particles alongside the test particles. The discovery could invalidate years of drug development data and force companies to redo costly biomarker studies and efficacy trials.EN

Researchers identified a panel of three microRNAs in blood that can distinguish prostate cancer from benign enlarged prostates with 73% accuracy. The finding could reduce unnecessary biopsies and improve screening efficiency, potentially reshaping how clinicians triage patients and opening a commercial opportunity for blood-based diagnostic companies.EN

Researchers discovered that standard blood sugar thresholds used to identify adults progressing toward type 1 diabetes produce misleading results when age is ignored. The finding could reshape how clinics screen and counsel at-risk patients, potentially avoiding unnecessary interventions for older adults while improving detection accuracy across age groups.EN

Researchers found that Matrix-M, a plant-derived immune booster, significantly enhances how cancer vaccines train the body's immune system to attack tumors. The discovery could accelerate development of preventive and therapeutic cancer vaccines, opening a new commercial avenue for pharmaceutical companies investing in personalized immunotherapy.EN

Researchers identified four bacterial gene clusters in healthy people that produce compounds protective against colorectal cancer, one resembling a known anticancer drug. The finding suggests the microbiome harbors untapped therapeutic compounds—opening new avenues for cancer prevention treatments and diagnostics that could shift screening and intervention strategies.EN

A major European trial is testing whether less invasive lymph node procedures can replace full surgical removal in breast cancer patients who respond well to chemotherapy. The findings could reshape treatment protocols, reduce patient complications, and lower surgical costs across oncology centers—potentially affecting how thousands of women are treated annually.EN

Scientists created a 3D tissue model that mimics how cancer grows alongside immune cells, then tested a new drug candidate on it. The advance could accelerate drug development by better predicting which compounds work in actual tumor environments before costly clinical trials.EN

WISDOM and MyPeBS, spanning thousands of women in the US and five European countries plus Israel, are delivering the first direct comparison of risk-based screening versus standard care. Early results suggest tailored screening strategies can safely catch cancers earlier while reducing unnecessary testing—potentially reshaping clinical guidelines and screening budgets globally.EN

A new drug combination pairing an immune-boosting agent with an established cancer therapy showed clinical activity in advanced breast cancer patients who had already failed other treatments. The results could expand options for a disease that remains incurable despite recent advances, potentially opening a new market segment for combination immunotherapies in oncology.EN

A major trial found that tailoring mammography frequency to individual genetic and clinical risk is as safe as annual screening for all women—while reducing overdiagnosis and expanding access to high-risk patients. The findings could reshape screening guidelines and reduce healthcare spending on low-risk populations.EN

A European study of 1,190 patients finds that some women whose tumors completely vanish after chemotherapy still relapse—and node involvement predicts who's at highest risk. The finding could reshape how oncologists monitor survivors and identify those needing intensified follow-up care or additional therapies.EN

Researchers have developed a highly sensitive method to spot ESR1 mutations in blood samples from hormone-resistant breast cancer patients. Early detection could let doctors switch treatments before tumors progress, potentially improving survival rates and reducing time spent on ineffective drugs.EN

A major international study of nearly 5,000 young women with BRCA mutations who developed breast cancer reveals wide variation in how doctors recommend surgery—from breast-conserving approaches to complete bilateral removal. The findings could reshape clinical guidelines and insurance coverage decisions for this high-risk population.EN

An international study of over 1,000 women with BRCA mutations found that those diagnosed before age 30 had significantly worse survival rates than those diagnosed between 36-40. The findings challenge assumptions about age and genetic risk, potentially reshaping screening protocols and treatment decisions for hereditary breast cancer patients.EN

Researchers used artificial intelligence to analyze 8,400 breast cancer biopsies and found that AI can identify aggressive tumor types and immune patterns that human pathologists alone might miss. The discovery could help oncologists decide which patients need stronger treatments, potentially sparing others from unnecessary chemotherapy.EN

A major clinical trial found that 1 in 33 women without prior breast cancer carry dangerous genetic mutations, far higher than previous estimates. The finding could reshape how insurers, health systems, and policymakers approach cancer screening and prevention for millions of asymptomatic women.EN

A new study of underground ants reveals that low-light conditions accelerate their response to chemical signals, yet this speed comes without sacrificing accuracy. The finding challenges conventional wisdom about speed-accuracy trade-offs in animal behavior and could reshape how researchers design experiments and how businesses optimize pest control strategies in subterranean environments.EN

Researchers have identified genetically distinct populations of the Eurasian Stone-curlew that were previously treated as a single species, revealing that conservation efforts may have overlooked critical biodiversity. The finding could force wildlife managers and policymakers to redesign protection plans for a bird species found across Europe, Asia, and Africa.EN

Researchers developed a machine learning system that identifies which coronaviruses are likely to infect humans with 97.8% accuracy by scanning spike protein sequences for two specific molecular patterns. The advance could accelerate early warning systems for emerging pathogens and help guide vaccine development priorities before outbreaks spread globally.EN

Researchers discovered that Asgard archaea—primitive microbes that predate complex cells—contain the molecular building blocks of microtubules, structures essential for cell division and organization in modern eukaryotes. The finding rewrites our understanding of how cells evolved and could inform biotechnology efforts to engineer cellular behavior.EN

En ny SCN9A-mutation hos isländsk familj öppnar vägen för bättre förståelse av smärtreglering och potentiella läkemedelsmål. En 73-årig man och hans två bröder bär en unik genetisk kombination — en tidigare känd mutation (p.Lys1659Ter) tillsammans med en helt ny deletion (c.417-15_4174-14delAT) som tar bort exon 23 och 18 aminosyror från natriumkanalen. Genom helgenomssekvensering bekräftade forskare vid Sahlgrenska och University of Iceland att denna sammansatt heterozygoti förklarar familjens medfödda smärtokänslighet utan att påverka andra neurologiska funktioner nämnvärt. Fyndet är relevant för läkemedelsutvecklare som söker selektiva SCN9A-hämmare för smärtbehandling. Mutationen visar exakt vilka proteindomäner som är icke-essentiella för normal neurologisk funktion, vilket reducerar risken för biverkningar vid framtida terapier. Denna precision gör studien värdefull för såväl målidentifiering som säkerhetsprofil.

Researchers have identified a metabolic approach to reverse mitochondrial damage in a rare genetic form of glaucoma caused by optineurin mutations. The finding could open a new drug development pathway for this blinding disease and potentially inform treatment strategies for other neurodegenerative conditions linked to cellular energy failure.EN

Researchers have developed a new class of drugs that hijack lysosomes—the cell's waste-disposal system—to selectively destroy disease-causing proteins and enable combination therapies. The approach could expand treatment options for cancers and other diseases where existing drugs have failed, potentially opening a new market for precision therapeutics.EN

Researchers developed new computational methods to identify and assess "cryptic pockets" on proteins—hidden molecular binding sites that were previously invisible to drug discovery. The advance could expand the pipeline of targetable proteins for pharmaceutical companies, potentially opening thousands of new drug development opportunities where traditional approaches found dead ends.EN